The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Introduction
============

Pakistan has a high prevalence of hyperuricemia \[[@REF1]\]. Although there is no large-scale epidemiological report, several smaller studies in this decade have reported a frequency of 30% to 39% \[[@REF1]-[@REF2]\]. Hyperuricemia most commonly results in gouty arthritis, which presents as tender, swollen, inflamed joints due to crystal deposition. Gouty arthritis is more commonly seen in men \[[@REF3]\].

Over time, researchers have linked gouty arthritis to cardiovascular comorbidity. Large epidemiological data have established a strong association of cardiovascular disease (CVD) with gouty arthritis \[[@REF4]-[@REF6]\]. Other studies have also established hyperuricemia, with or without gout, as a precursor and independent risk factor for a range of CVDs including hypertension (HTN), metabolic syndrome, and coronary artery disease (CAD) \[[@REF7]-[@REF10]\]. In a recent study with 2000+ patients, Ranjith et al. determined that increased serum uric acid (sUA) was not only significantly with associated with HTN and renal dysfunction but also major adverse cardiac events (MACE). They also concluded that acute myocardial infarction (AMI) patients with hyperuricemia had an increased risk of mortality \[[@REF11]\]. The possible explanation for an increased risk of CVD in patients with hyperuricemia can be the role of uric acid in HTN, oxidative stress, endothelial dysfunction and metabolic syndrome \[[@REF11]\].

As discussed above, the frequency of hyperuricemia in Pakistan is 30% to 39% and the frequency of CVDs is 17.5% \[[@REF2]-[@REF3],[@REF12]\]. However, to the best of our knowledge, no study has been conducted to evaluate the correlation between the two in our population. Hence, in this study, we aimed to assess sUA levels in patients with AMI and compare them with healthy adults.

Materials and methods
=====================

We conducted a case-control study in a tertiary public hospital in Pakistan. This study was conducted from 1st March to 30th November, 2019. All patients were included after attaining informed consent. The study was approved by the institutional review board.

Patients who were admitted with AMI within the last 24 hours, confirmed by history, electrocardiogram (ECG), and cardiac biomarkers were included as "cases". Their healthy counterparts were randomly recruited from the attendants of the patients as "controls". For both groups, demographic and clinical characters including gender, age, smoking status, comorbidities, previous history of myocardial infarction, family cardiac history, and use of thiazide were recorded. Peripheral venous blood samples were collected within 24 h to determine sUA levels from the in-hospital laboratory facility. Hyperuricemia was defined as sUA levels greater than 5.8 mg/dl in women and 7 mg/dl in men \[[@REF13]\].

Statistical analysis was done using SPSS v. 22.0 (IBM Corp., Armonk, NY, US). Continuous variables were analyzed via descriptive statistics and were presented as mean and standard deviation (SD) while categorical variables were presented by percentages and frequencies. An independent sample T-test was applied to compare continuous variables. Chi-square was applied to compare categorical variables. P-value ≤0.05 was taken as significant.

Results
=======

This study was completed by 119 cases and 119 controls. Their demographic characteristics such as age, smoking status, co-morbidities such as smoking, diabetes, hypertension, and other risk factors for AMI were comparable between the two groups. Mean uric acid levels were significantly higher in patients with AMI in comparison to the control group (Table [1](#TAB1){ref-type="table"}).

###### Comparison of demographic and clinical characteristics of the cases and the controls

AMI, acute myocardial infarction

  ------------------------------- ----------------- --------------------- ---------
  Patient characteristics         Cases (n = 119)   Controls  (n = 119)   P-value
  Age in years                    58 ± 17           55 ± 19               0.20
  Gender                                                                  
  Male                            71 (59.66%)       66 (55.46%)           0.43
  Female                          48 (40.33%)       53 (44.53%)           
  Active smoking                  51 (42.85%)       53 (44.53%)           0.79
  Diabetes mellitus               31 (26.05%)       25 (21.00%)           0.84
  Hypertension                    61 (51.26%)       56 (47.05%)           0.51
  Use of Thiazides                31 (26.05%)       27 (22.68%)           0.54
  Previous history of AMI         9 (7.56%)         6 (5.04%)             0.42
  Family history of AMI           12 (10.08%)       11 (9.24%)            0.82
  Mean serum uric acid in mg/dl   6.17 ± 2.12       5.51 ± 1.89           0.01
  ------------------------------- ----------------- --------------------- ---------

The sUA level was then categorized according to patient gender. In both cases and controls, men had a higher frequency of hyperuricemia than women. Men in the cases group had a higher frequency of hyperuricemia than men in the controls (53% vs. 36%). The differences were statistically significant (*p *= 0.04). The frequency of hyperuricemia in women of both groups did not differ statistically. Overall, cases had a higher frequency of hyperuricemia than controls (48% vs. 33%). The differences were statistically significant (*p *= 0.04). All data are summarized in Table [2](#TAB2){ref-type="table"}.

###### Frequency of hyperuricemia deficiency in the cases and the controls

  ----------------- ---------------------------- ------------- ------
  Gender            Frequency of hyperuricemia   P-value       
  Cases (n = 119)   Controls  (n = 119)                        
  Male              38 (53.52%)                  24 (36.36%)   0.04
  Female            19 (39.58%)                  16 (30.1%)    0.32
  Total             57 (47.89%)                  40 (33.6%)    0.04
  ----------------- ---------------------------- ------------- ------

Discussion
==========

Hyperuricemia has been correlated with various diseases such as hypertension, hyperlipidemia, diabetes, metabolic syndrome, and renal disease, which all have contributed to increased coronary heart disease (CHD) and all-cause mortality. In this study, mean uric acid was higher in patients with AMI compared to the control group. In addition, there were more patients with hyperuricemia in case group compared to control group. There were fifty-seven (47.89%) participants with hyperuricemia in patients. The control population had 33.6% participants with hyperuricemia. This was comparable to hyperuicemia reported in other local literature \[[@REF1]\]. In our study, the association was significant for men as compared to women. This was in contrast to the results of a meta-analysis where hyperuricemia was associated with the risk of CAD-related mortality; however, the association was stronger for women than men \[[@REF14]\].

There have been various explanations to the association of high sUA with CVDs. One model postulates that uric acid is one of the risk factors for endothelial dysfunction, which plays a major role in cardiovascular diseases. Uric acid increases high mobility group box chromosomal protein 1 (HMGB1) expression and extracellular release in endothelial cells. HMGB1, which is an inflammatory cytokine, interacts with the Receptor for Advanced Glycation products (RAGE) which leads to oxidative stress and inflammatory response, which causes endothelial dysfunction \[[@REF15]\]. RAGE has been associated with atherosclerosis as it is expressed on various cells such as due to its expression on the surface of a wide variety of cells, such as endothelial cells, lymphocytes, monocyte-derived macrophages, and vascular smooth muscle cells, that are responsible for the pathogenesis of atherosclerosis \[[@REF16]\]. Other studies have also studied the role of uric acid in endothelial dysfunction \[[@REF17]-[@REF18]\].

Among our AMI patients, 57 (47.89%) had hyperuricemia as compared to 40 (33.6%) controls. Mean uric acid levels were also higher in AMI patients. In an Indian study, the sUA levels were higher in patients of AMI correlated with Killip class \[[@REF19]\]. Li-chen established that not only higher sUA is associated with increased myocardial infarction incidence but also patients with higher uric acid had a higher rate of left systolic dysfunction and diastolic dysfunction and were likely to have more in-hospital MACEs \[[@REF20]\].

The study has its limitations. First, since it was a case-control study, a strong correlation could not be established. A prospective cohort study is needed to further establish uric acid as the risk factor for AMI in the Pakistani population. Second, since it was a single-center study, the result could not be inferred to a larger population.

Conclusions
===========

In this study, uric acid levels were higher in patients with AMI and there were more patients with hyperuricemia compared to the control group. Uric acid should be considered as a strong risk factor for AMI and should be included in general screening by cardiologists and health-care professionals. Furthermore, a large-scale prospective cohort study is needed to establish the correlation between uric acid and AMI.
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